Overview

At Oruka, we apply state-of-the-art antibody engineering to validated modes of action to develop biologics with the potential to redefine the standard of care for psoriasis, psoriatic arthritis, and other indications.

Our lead programs, ORKA-001 and ORKA-002, are designed to block cytokines that play key roles in the pathogenesis of psoriasis and other inflammatory diseases. ORKA-001 targets the p19 subunit of interleukin-23 (IL-23p19) and ORKA-002 targets interleukin-17A and interleukin-17F (IL-17A/F). We have optimized ORKA-001 and ORKA-002 with the aim of perfecting the product profile we can offer and enabling patients to experience the greatest possible freedom from disease.